Thank you for providing the complete ProTox-3.0 prediction report.
This analysis evaluates
the potential of the compound as a future brain cancer drug by assessing toxicity risks, blood-
brain barrier (BBB) penetration, receptor binding, metabolism, and molecular features —
and suggests modifications to enhance drug-likeness and reduce risk.
🧪 1. Key Molecular and Pharmacological Properties
Property Value Interpretation
Molecular Weight 286.32 g/mol ✅ Drug-like (ideal < 500 g/mol)
H-bond Acceptors / 4 acceptors / 1
✅ Suitable for oral and CNS-active drugs
Donors donor
Topological Polar Surface
63.6 Ų ✅ Good BBB permeability (< 90 Ų)
Area
logP (lipophilicity) 3.45 ✅ Ideal for CNS drugs (2–5)
⚠️Toxicity Class 4 – moderate toxicity (lower is worse;
LD50 (oral) 1000 mg/kg
ideal > 2000 mg/kg)
Cytotoxicity Active (0.82) ✅ Promising for cancer treatment
Neurotoxicity Inactive (0.70) ✅ Safe for brain/neuron use
BBB permeability Active (0.67) ✅ Can reach brain tumors
Mutagenicity / Inactive (0.74 /
✅ Low risk of DNA damage or cancer
Carcinogenicity 0.57)
⚠️Major concern — could suppress or disrupt immune
Immunotoxicity Active (0.99)
system
Nephrotoxicity / Active (0.51 /
⚠️Possible kidney and lung side effects
Respiratory 0.65)
Clinical Toxicity Active (0.53) ⚠️Likely systemic adverse effects
🔬 2. Receptor & Pathway Binding (Tox21 + MIE)
Target/Pathway Status Relevance
Transthyretin (TTR) Active ✅ May aid CNS delivery (TTR helps transport thyroid
Target/Pathway Status Relevance
(0.57) hormones to brain)
Active ⚠️Potential CNS side effects (sedation, seizures if not
GABA receptor (GABAR)
(0.51) targeted correctly)
Active ⚠️Can cause drug-drug interactions; affects metabolism
PXR (Pregnane X receptor)
(0.56) and drug clearance
All other hormone-related
Inactive ✅ No unwanted endocrine disruption
receptors
🔬 3. CYP450 Metabolism Profile
Cytochrome Enzymes Status Implication
Active (0.62 / ⚠️Metabolized by these enzymes; risk of variable clearance or
CYP2C9 / CYP2C19
0.52) interactions
CYP1A2, CYP3A4,
Inactive ✅ Less chance of broad-spectrum interactions
CYP2D6
CYP2E1 Inactive (0.99) ✅ No risk of toxic metabolites from this enzyme
🧠 4. Brain Cancer Drug Requirements vs. Current
Compound
Criterion Status Action Needed
BBB Penetration ✅ Active Retain
Cytotoxicity ✅ Active Retain
Neurotoxicity ✅ Inactive Good
Immunotoxicity ⚠️Active (0.99) Must be reduced
Minimize via structural modification or
Respiratory/Nephrotoxicity ⚠️Active
formulation
Drug-drug interaction risk (PXR) ⚠️Moderate Reduce PXR activation
Criterion Status Action Needed
Receptor specificity (TTR, Mixed – promising but
Enhance specificity for tumor cells only
GABAR) risky
🛠️5. Recommended Modifications to Improve Brain Cancer
Drug Profile
Area Issue Suggested Solution
Remove or modify electrophilic / immunogenic
Immunotoxicity Too high (0.99)
groups (e.g., nitro, halogens)
Reduce lipophilicity slightly; avoid renal-excreted
Nephrotoxicity Borderline active (0.51)
metabolites
Respiratory Adjust aromatic substitutions to reduce off-target
Active (0.65)
Toxicity reactivity in lungs
Active (0.51) – may cause Introduce steric hindrance near the GABA-like region
GABAR Binding
CNS side effects or reduce CNS receptor mimicry
PXR Activation Active (0.56) Avoid bulky, lipophilic side chains that mimic steroids
Oral Toxicity (Class Moderate (LD50: 1000
Optimize structure to increase LD50 > 2000 mg/kg
4) mg/kg)
🌟 6. Optimized Drug Characteristics
After applying the above modifications, the compound could possess:
Trait Optimized Outcome
✅ Crosses the BBB Reaches brain tumors efficiently
✅ Tumor-selective cytotoxicity Kills brain cancer cells (like glioblastoma)
✅ Neuro-safe Does not harm healthy neurons
✅ Low mutagenicity/carcinogenicity Safe for long-term use
✅ Immuno-safe Does not impair the immune system
✅ Acceptable oral toxicity LD50 improves to Class 5–6 (>2000 mg/kg)
Trait Optimized Outcome
✅ Balanced metabolism Less chance of interactions via CYP450/PXR pathways
✍️Conclusion Summary
The compound currently exhibits strong potential as a brain cancer therapeutic due to its BBB
permeability, cytotoxic activity, and neuro-safety. However, to make it truly promising,
structural refinement is essential to mitigate its immunotoxicity, nephrotoxicity, and PXR-
mediated metabolism issues. These changes would transform it into a selective, brain-
penetrant, and systemically safe anti-cancer agent fit for further preclinical development.
Would you like help designing specific structure modifications or generating a 3D
pharmacophore model next?